Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts HARP Hot Sheet
Price: $23.01 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 13
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee initiates coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.
Shares of Harpoon Therapeutics closed at $17.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts TechnipFMC (FTI) at Buy
- Deutsche Bank Starts Columbia Banking System (COLB) at Hold
- Rothschild Redburn Starts MiniMed Group (MMED) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
